2021
DOI: 10.3892/mmr.2021.11964
|View full text |Cite
|
Sign up to set email alerts
|

Application of nanotechnology in drug delivery systems for respiratory diseases (Review)

Abstract: Respiratory disease is a common disease with a high incidence worldwide, which is a serious threat to human health, and is considered a societal and economic burden. The application of nanotechnology in drug delivery systems has created new treatments for respiratory diseases. Within this context, the present review systematically introduced the physicochemical properties of nanoparticles (NPs); reviewed the current research status of different nanocarriers in the treatment of respiratory diseases, including l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
37
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
3
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(37 citation statements)
references
References 116 publications
0
37
0
Order By: Relevance
“…NPs have also successfully aided in reducing drug toxicity and side effects due to high efficacy delivery that ensures therapeutic potential in minimal dosage, supports sustained drug release, and alters drug distribution, as well as clearance [5]. The National Nanotechnology Initiative (NNI) in the year 2000 by the US National Science and Technology Council (NSTC) facilitated the realization and translation of nanotechnology in clinical settings, and since then, multiple studies have recorded the significance of NPs in respiratory diseases, kidney diseases, and antibacterial and anticancer agents [6][7][8]. Although research has documented significant strides in application of NPs, the translation at patient levels is low majorly due to patient heterogeneity, as well as difference in physiology between animals and humans [9].…”
Section: Introductionmentioning
confidence: 99%
“…NPs have also successfully aided in reducing drug toxicity and side effects due to high efficacy delivery that ensures therapeutic potential in minimal dosage, supports sustained drug release, and alters drug distribution, as well as clearance [5]. The National Nanotechnology Initiative (NNI) in the year 2000 by the US National Science and Technology Council (NSTC) facilitated the realization and translation of nanotechnology in clinical settings, and since then, multiple studies have recorded the significance of NPs in respiratory diseases, kidney diseases, and antibacterial and anticancer agents [6][7][8]. Although research has documented significant strides in application of NPs, the translation at patient levels is low majorly due to patient heterogeneity, as well as difference in physiology between animals and humans [9].…”
Section: Introductionmentioning
confidence: 99%
“…Biodegradable Polymer based nanoparticles are gaining great momentum in the development of the NPs for the development of DDS of diversified drug entities ( Luo et al, 2021 , Allam et al, 2020 ). Biodegradable NPs imitates nano-size that assist the drug to permeate and cross the lipoidal biological cell membrane with consequent improvement in the solubility, permeability, absorption, and bioavailability.…”
Section: Introductionmentioning
confidence: 99%
“…Nanoparticle formulation strategies can be used to alter the way in which active compounds are presented within the body [61][62][63][64][65], including modification of their dissolution profiles [66][67][68][69][70], and some of these strategies have been adapted specifically for pulmonary delivery [71][72][73][74]. In some instances, nanoparticles can help overcome specific pharmaceutical development challenges including increased payload delivery, controlled-release kinetics to optimize pharmacokinetic (PK)/pharmacodynamic (PD), improvement of efficacy, and reduction of adverse events [64,75,76].…”
Section: Strategies To Overcome Biological Barriersmentioning
confidence: 99%